The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors - PubMed (original) (raw)
Review
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
Eric K Rowinsky. Annu Rev Med. 2004.
Abstract
The overexpression and aberrant function of members of the erbB family of receptors, particularly erbB1 (also known as epidermal growth factor receptor), and its ligands in many human cancers have provided a rationale for targeting this signaling network with novel approaches. erbB1 is a selective target for inhibiting cancers because its activation often confers a proliferative advantage. Activation of the erbB1 tyrosine kinase provides signals that drive dysregulated proliferation, invasion, metastasis, angiogenesis, and cell survival, and its inhibition has potential in both the treatment and prevention of these malignancies. Based on the structure and function of erbB1, two therapeutic strategies have been developed. The first uses human monoclonal antibodies (MAbs) generated against the receptor's ligand-binding extracellular domain. These MAbs block binding of receptor-activating ligands, and, in some cases, can induce receptor endocytosis and downregulation. The second uses small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thereby blocking receptor activation and the transduction of postreceptor signals. Early clinical studies suggest that both approaches are well tolerated and can induce clinical activity in many common malignancies.
Similar articles
- The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Ritter CA, Arteaga CL. Ritter CA, et al. Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11. doi: 10.1053/sonc.2003.50027. Semin Oncol. 2003. PMID: 12644979 Review. - ErbB-targeted therapeutic approaches in human cancer.
Arteaga CL. Arteaga CL. Exp Cell Res. 2003 Mar 10;284(1):122-30. doi: 10.1016/s0014-4827(02)00104-0. Exp Cell Res. 2003. PMID: 12648471 Review. - Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.
Arteaga CL. Arteaga CL. Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9. doi: 10.1053/sonc.2002.35642. Semin Oncol. 2002. PMID: 12422308 Review. - Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Bianco R, et al. Int J Biochem Cell Biol. 2007;39(7-8):1416-31. doi: 10.1016/j.biocel.2007.05.008. Epub 2007 May 21. Int J Biochem Cell Biol. 2007. PMID: 17596994 Review.
Cited by
- Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Tardito S, et al. Int J Mol Sci. 2024 Jun 28;25(13):7131. doi: 10.3390/ijms25137131. Int J Mol Sci. 2024. PMID: 39000238 Free PMC article. Review. - The EGFR phosphatase RPTPγ is a redox-regulated suppressor of promigratory signaling.
Joshi MS, Stanoev A, Huebinger J, Soetje B, Zorina V, Roßmannek L, Michel K, Müller SA, Bastiaens PI. Joshi MS, et al. EMBO J. 2023 May 15;42(10):e111806. doi: 10.15252/embj.2022111806. Epub 2023 Mar 29. EMBO J. 2023. PMID: 36988334 Free PMC article. - The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.
Smok-Kalwat J, Mertowska P, Mertowski S, Smolak K, Kozińska A, Koszałka F, Kwaśniewski W, Grywalska E, Góźdź S. Smok-Kalwat J, et al. Int J Mol Sci. 2023 Jan 12;24(2):1506. doi: 10.3390/ijms24021506. Int J Mol Sci. 2023. PMID: 36675020 Free PMC article. Review. - Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.
Kozyra P, Pitucha M. Kozyra P, et al. Int J Mol Sci. 2022 Aug 9;23(16):8874. doi: 10.3390/ijms23168874. Int J Mol Sci. 2022. PMID: 36012142 Free PMC article. Review. - Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes.
Tsumura T, Doi K, Marusawa H. Tsumura T, et al. Cancers (Basel). 2022 Jul 28;14(15):3674. doi: 10.3390/cancers14153674. Cancers (Basel). 2022. PMID: 35954337 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous